JP2006514923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514923A5 JP2006514923A5 JP2004546264A JP2004546264A JP2006514923A5 JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5 JP 2004546264 A JP2004546264 A JP 2004546264A JP 2004546264 A JP2004546264 A JP 2004546264A JP 2006514923 A5 JP2006514923 A5 JP 2006514923A5
- Authority
- JP
- Japan
- Prior art keywords
- depot preparation
- preparation according
- injectable depot
- ziprasidone
- sbecd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003405 delayed action preparation Substances 0.000 claims 13
- 229920000858 Cyclodextrin Polymers 0.000 claims 7
- -1 aryl heterocyclic compound Chemical class 0.000 claims 7
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000011345 viscous material Substances 0.000 claims 5
- 229960000607 ziprasidone Drugs 0.000 claims 5
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 238000010255 intramuscular injection Methods 0.000 claims 3
- 239000007927 intramuscular injection Substances 0.000 claims 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 3
- 229960004487 ziprasidone mesylate Drugs 0.000 claims 3
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001897 terpolymer Polymers 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229930182556 Polyacetal Natural products 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000008135 aqueous vehicle Substances 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001444 polymaleic acid Polymers 0.000 claims 1
- 229920000056 polyoxyethylene ether Polymers 0.000 claims 1
- 229940051841 polyoxyethylene ether Drugs 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42147302P | 2002-10-25 | 2002-10-25 | |
| PCT/IB2003/004576 WO2004037289A2 (en) | 2002-10-25 | 2003-10-13 | Novel injectable depot formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514923A JP2006514923A (ja) | 2006-05-18 |
| JP2006514923A5 true JP2006514923A5 (https=) | 2006-11-24 |
Family
ID=32176718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004546264A Abandoned JP2006514923A (ja) | 2002-10-25 | 2003-10-13 | 注射可能な新規なデポ製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040138237A1 (https=) |
| EP (1) | EP1575616A2 (https=) |
| JP (1) | JP2006514923A (https=) |
| KR (1) | KR20050055781A (https=) |
| CN (1) | CN1849110A (https=) |
| AR (1) | AR041722A1 (https=) |
| AU (1) | AU2003267788A1 (https=) |
| BR (1) | BR0315568A (https=) |
| CA (1) | CA2503076A1 (https=) |
| MX (1) | MXPA05002561A (https=) |
| NL (1) | NL1024590C2 (https=) |
| NO (1) | NO20052463L (https=) |
| PA (1) | PA8586201A1 (https=) |
| PE (1) | PE20040499A1 (https=) |
| PL (1) | PL377679A1 (https=) |
| RU (1) | RU2310450C2 (https=) |
| TW (1) | TW200423941A (https=) |
| UY (1) | UY28038A1 (https=) |
| WO (1) | WO2004037289A2 (https=) |
| ZA (1) | ZA200501921B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| ATE482695T1 (de) | 2002-12-13 | 2010-10-15 | Durect Corp | Orale darreichungsform mit flüssigen hochviskosen trägersystemen |
| MXPA06002455A (es) * | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
| AU2005287175B2 (en) * | 2004-09-17 | 2011-12-01 | Durect Corporation | Sustained local anesthetic composition containing preferably a sugar ester such as SAIB |
| EP1855651A4 (en) * | 2005-03-03 | 2011-06-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES |
| RU2407529C2 (ru) * | 2005-04-13 | 2010-12-27 | Пфайзер Продактс Инк. | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| EP1874267A1 (en) * | 2005-04-13 | 2008-01-09 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
| WO2007027273A1 (en) * | 2005-06-20 | 2007-03-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| KR100908517B1 (ko) * | 2006-07-04 | 2009-07-20 | (주)아모레퍼시픽 | 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법 |
| US8337883B2 (en) | 2006-11-03 | 2012-12-25 | Durect Corporation | Transdermal delivery systems |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| US20110144202A1 (en) * | 2008-06-16 | 2011-06-16 | Uwe Marx | Concentrated oxaliplatin solution and its method of preparation |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| TW201521769A (zh) | 2013-03-15 | 2015-06-16 | Durect Corp | 具有流變改質劑以減少溶解變異性之組成物 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CN104688686A (zh) * | 2015-02-10 | 2015-06-10 | 万全万特制药江苏有限公司 | 一种含有齐拉西酮及其盐的脂肪乳注射剂 |
| SG11201811760VA (en) | 2016-07-06 | 2019-01-30 | Durect Corp | Oral dosage form with drug composition, barrier layer and drug layer |
| WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| GB2579707A (en) | 2018-10-15 | 2020-07-01 | Avent Inc | Compositions, systems, kits, and methods for neural ablation |
| CN115666621A (zh) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | 具有减少的杂质的持续释放药物递送系统及相关方法 |
| CA3203561A1 (en) | 2021-01-12 | 2022-07-21 | Adrian Neil Verity | Sustained release drug delivery systems and related methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029782A (en) * | 1975-04-28 | 1977-06-14 | Eli Lilly And Company | Cefazolin suspension for parenteral administration |
| US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| JP4642946B2 (ja) * | 1996-12-20 | 2011-03-02 | アルザ コーポレイション | ゲル組成物および方法 |
| US6117949A (en) * | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6201072B1 (en) * | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| EP1073432B1 (en) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| ATE234097T1 (de) * | 1999-05-27 | 2003-03-15 | Pfizer Prod Inc | Ziprasidonsuspension |
| US6753011B2 (en) * | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
-
2003
- 2003-10-13 RU RU2005112207/15A patent/RU2310450C2/ru not_active IP Right Cessation
- 2003-10-13 CN CNA2003801019024A patent/CN1849110A/zh active Pending
- 2003-10-13 AU AU2003267788A patent/AU2003267788A1/en not_active Abandoned
- 2003-10-13 PL PL377679A patent/PL377679A1/pl not_active Application Discontinuation
- 2003-10-13 CA CA002503076A patent/CA2503076A1/en not_active Abandoned
- 2003-10-13 JP JP2004546264A patent/JP2006514923A/ja not_active Abandoned
- 2003-10-13 EP EP03748483A patent/EP1575616A2/en not_active Withdrawn
- 2003-10-13 BR BR0315568-4A patent/BR0315568A/pt not_active IP Right Cessation
- 2003-10-13 MX MXPA05002561A patent/MXPA05002561A/es unknown
- 2003-10-13 WO PCT/IB2003/004576 patent/WO2004037289A2/en not_active Ceased
- 2003-10-13 KR KR1020057006986A patent/KR20050055781A/ko not_active Ceased
- 2003-10-14 PA PA20038586201A patent/PA8586201A1/es unknown
- 2003-10-21 US US10/690,078 patent/US20040138237A1/en not_active Abandoned
- 2003-10-22 NL NL1024590A patent/NL1024590C2/nl not_active IP Right Cessation
- 2003-10-22 PE PE2003001071A patent/PE20040499A1/es not_active Application Discontinuation
- 2003-10-24 TW TW092129568A patent/TW200423941A/zh unknown
- 2003-10-24 UY UY28038A patent/UY28038A1/es not_active Application Discontinuation
- 2003-10-24 AR ARP030103894A patent/AR041722A1/es not_active Application Discontinuation
-
2005
- 2005-03-07 ZA ZA200501921A patent/ZA200501921B/xx unknown
- 2005-05-23 NO NO20052463A patent/NO20052463L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514923A5 (https=) | ||
| JP2006514923A (ja) | 注射可能な新規なデポ製剤 | |
| CN100374112C (zh) | 罗替戈汀鼻内组合物 | |
| EP1312356B1 (en) | Aqueous suspension preparations | |
| JP2005514349A5 (https=) | ||
| US5773608A (en) | Process for preparing stabilized chitin derivative compounds | |
| US20090047330A1 (en) | Oral fast dissolving films for erectile dysfunction bioactive agents | |
| JP2004510807A5 (https=) | ||
| JP2006528990A5 (https=) | ||
| CA2717605A1 (en) | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | |
| IT1243390B (it) | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. | |
| JP2003512341A5 (https=) | ||
| TR200101088T2 (tr) | Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu | |
| JP2006505579A (ja) | 懸濁形態でのアリール複素環活性薬物の蓄積製剤 | |
| DK1968638T3 (en) | Controlled release gels | |
| US20100267817A1 (en) | Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same | |
| JPH1072376A (ja) | ヒアルロン酸含有点眼水溶液 | |
| CN100444828C (zh) | 一种生物降解聚合物药物微球的制备方法 | |
| KR102421758B1 (ko) | 안과용 조성물 | |
| JPH092977A (ja) | 経口投与用医薬組成物 | |
| JP2006052172A5 (https=) | ||
| JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
| JP2005527615A (ja) | ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 | |
| 王雅琪 et al. | The effects of characteristics of chitosan on the heparin loaded chitosan microspheres | |
| WO1997007139A2 (en) | Stabilized chitin derivative compounds |